Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Assets Average (2021 - 2025)

SAB Biotherapeutics' Assets Average history spans 5 years, with the latest figure at $178.1 million for Q4 2025.

  • For Q4 2025, Assets Average rose 263.56% year-over-year to $178.1 million; the TTM value through Dec 2025 reached $178.1 million, up 263.56%, while the annual FY2025 figure was $108.5 million, 69.35% up from the prior year.
  • Assets Average reached $178.1 million in Q4 2025 per SABSW's latest filing, up from $106.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $178.1 million in Q4 2025 to a low of $31.9 million in Q3 2023.
  • Average Assets Average over 5 years is $72.6 million, with a median of $60.9 million recorded in 2022.
  • Peak YoY movement for Assets Average: crashed 52.18% in 2022, then soared 263.56% in 2025.
  • A 5-year view of Assets Average shows it stood at $99.0 million in 2021, then plummeted by 47.79% to $51.7 million in 2022, then grew by 8.57% to $56.1 million in 2023, then dropped by 12.72% to $49.0 million in 2024, then skyrocketed by 263.56% to $178.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Assets Average are $178.1 million (Q4 2025), $106.8 million (Q3 2025), and $34.1 million (Q2 2025).